GREG CHOW, M.B.A.
Chief Financial Officer
“The Company is uniquely positioned at the forefront of ADC innovation, with a robust pipeline, high value collaborations, and a powerful cell-free technology platform that enables precise, efficient drug discovery.”
Greg Chow has served as our Chief Financial Officer since June 2025, bringing over 25 years of experience in corporate finance, capital markets, drug development operations, and business development. Prior to joining Sutro, Mr. Chow served as CFO and CBO at NodThera, and held CFO roles at Freenome Holdings, Inc., Frontier Medicines Corp., and Aptose Biosciences, Inc. (Nasdaq: APTO).
Earlier in his career, Greg spent fourteen years in investment banking, including leadership roles as Managing Director and Director of Private Placements at Wedbush Securities, and senior roles at RBC Capital Markets and Wells Fargo Securities.
Mr. Chow holds an MBA in Finance from The Wharton School at the University of Pennsylvania and a BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara. Mr. Chow is also a Certified Public Accountant (inactive) in the State of California.